



This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) A compound of the Formula Ia:



or a pharmaceutically acceptable salt or solvate thereof
wherein,

- L- is a Ligand unit;
- A- is a Stretcher unit;
- a is 0 or 1;
- each -W- is independently an Amino Acid unit;
- Y- is a Spacer unit;
- w is an integer ranging from 0 to 12;
- y is 0, 1 or 2;
- p ranges from 1 to about 20; and
- D is a Drug unit of the formula



wherein, independently at each location:

- R² is selected from -H and -C₁-C₈ alkyl;
- R³ is selected from -H, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkyl), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle);
- R⁴ is selected from -H, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkyl), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle) wherein R⁵ is selected from -H and -methyl; or R⁴ and R⁵ join, have the formula

$-(CR^aR^b)_n-$ wherein R^a and R^b are independently selected from -H, $-C_1-C_8$ alkyl and $-C_3-C_8$ carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;


R^6 is selected from -H and $-C_1-C_8$ alkyl;

R^7 is selected from -H, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle);

each R^8 is independently selected from -H, -OH, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle and $-O-(C_1-C_8$ alkyl);

R^9 is selected from -H and $-C_1-C_8$ alkyl;

R^{10} is selected from



Z is -O-, -S-, -NH- or $-N(R^{14})-$;

R^{11} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle); or R^{11} is an oxygen atom which forms a carbonyl unit ($C=O$) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the ($C=O$) double bond;

each R^{12} is independently selected from -aryl and $-C_3-C_8$ heterocycle;


R^{13} is selected from -H, -OH, $-NH_2$, $-NHR^{14}$, $-N(R^{14})_2$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, $-O-(C_1-C_8$ alkyl), -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle); and

Each R^{14} is independently -H or $-C_1-C_8$ alkyl.

2. (Original) The compound of claim 1 wherein w is an integer ranging from 2 to 12.

3-6. (Canceled)

7. (Currently Amended) A compound of the formula Ia:



or a pharmaceutically acceptable salt or solvate thereof ~~of the compound of claim 1~~
wherein,

L- is a Ligand unit;

-A- is a Stretcher unit;

a is 0 or 1;

each -W- is independently an Amino Acid unit;


-Y- is a Spacer unit;

w is an integer ranging from 0 to 12;

y is 0, 1 or 2;

p ranges from 1 to about 20; and

[[where]] -D is a Drug unit having the structure



wherein, independently at each location:

R² is selected from -H and -methyl;


R³ is selected from -H, -methyl, and -isopropyl;

R^4 is selected from -H and -methyl; R^5 is selected from -isopropyl, -isobutyl, -sec-butyl, -methyl and -t-butyl or R^4 and R^5 join, have the formula $-(CR^aR^b)_n$ where R^a and R^b are independently selected from -H, $-C_1-C_8$ alkyl, and $-C_3-C_8$ carbocycle, and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R^6 is selected from -H and -methyl;

each R^8 is independently selected from -OH, -methoxy and -ethoxy;

R^{10} is selected from



R^{24} is selected from H and $-C(O)R^{25}$; wherein R^{25} is selected from $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle);


Z is -O-, -NH-, -OC(O)-, -NHC(O)-, $-NR^{28}C(O)-$; where R^{28} is selected from -H and $-C_1-C_8$ alkyl;

n is 0 or 1; and

R^{27} is selected from -H, $-N_3$, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle) when n is 0; and R^{27} is selected from -H, $-C_1-C_8$ alkyl, $-C_3-C_8$ carbocycle, -aryl, $-C_1-C_8$ alkyl-aryl, $-C_1-C_8$ alkyl- $(C_3-C_8$ carbocycle), $-C_3-C_8$ heterocycle and $-C_1-C_8$ alkyl- $(C_3-C_8$ heterocycle) when n is 1.

8. (Canceled)

9. (Original) A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -D is a Drug unit having the structure




10-16. (Canceled)

17. (Previously Presented) A compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where the Ligand unit is an antibody unit.

18. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 17 where the antibody unit is a monoclonal antibody unit.


19. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 18 where the monoclonal antibody unit is ~~eBR96, eAC10 or 1F6~~ specifically binds the CD30 antigen, the CD70 antigen, the CD20 antigen, or the Lewis antigen.

20. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -Y_y- is




Q is selected from -C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -halogen, -nitro and -cyano; and m is an integer ranging from 0-4, the amino terminus of -Y_y- forming a bond with an Amino acid unit and the carboxyl terminus of -Y_y- forming a bond with an Drug unit.

21. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

22. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

23. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

24. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

25. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




and r is an integer ranging from 1-10, the carbonyl terminus of -A- forming a bond with an Amino acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

26. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim [[1]] 120 where -A- is




the carbonyl terminus of -A- forming a bond with an Amino acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

27. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 21 where -A- is




the carbonyl terminus of -A- forming a bond with an Amino acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

28. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 22 where -A- is



the carbonyl terminus of -A- forming a bond with an Amino acid unit and the amidomethyl terminus of -A- forming a bond with a Ligand unit.

29. (Original) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 24 where -A- is




the carbonyl terminus of -A- forming a bond with an Amino acid unit and the succinimido terminus of -A- forming a bond with a Ligand unit.

30. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -W_w- is -Phenylalanine-Lysine-~~or valine~~~~-citrulline-~~, the amino terminus of -W_w- forming a bond with a Stretcher unit ~~when a is 1 or~~
~~with a Ligand unit if a is 0~~, and the C- terminus of -W_w- forming a bond with a Spacer unit ~~when y is 1 or 2, and with a Drug unit when y is 0.~~

31-43. (Canceled)

44. (Currently Amended) A compound of the formula



or a pharmaceutically acceptable salt or solvate thereof

wherein, independently at each location:

R² is selected from -H and -C₁-C₈ alkyl;

R³ is selected from -H, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkoxy), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle);

R⁴ is selected from -H, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkoxy), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle) wherein R⁵ is selected from -H and -methyl; or R⁴ and R⁵ join, have the formula -(CR^aR^b)_n wherein R^a and R^b are independently selected from -H, -C₁-C₈ alkyl and -C₃-C₈ carbocycle and n is selected from 2, 3, 4, 5 and 6, and form a ring with the carbon atom to which they are attached;

R⁶ is selected from -H and -C₁-C₈ alkyl;

R⁷ is selected from -H, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkoxy), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle);

each R⁸ is independently selected from -H, -OH, -C₁-C₈ alkyl, -C₃-C₈ carbocycle and -O-(C₁-C₈ alkoxy);

R⁹ is selected from -H and -C₁-C₈ alkyl;

R¹¹ is selected from -H, -OH, -NH₂, -NHR¹⁴, -N(R¹⁴)₂, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkyl), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle); or R¹¹ is an oxygen atom which forms a carbonyl unit (C=O) with the carbon atom to which it is attached and a hydrogen atom on this carbon atom is replaced by one of the bonds in the (C=O) double bond;

each R¹² is independently selected from -aryl and -C₃-C₈ heterocycle;

R^{13} is selected from -H, -OH, -NH₂, -NHR¹⁴, -N(R¹⁴)₂, -C₁-C₈ alkyl, -C₃-C₈ carbocycle, -O-(C₁-C₈ alkoxy), -aryl, -C₁-C₈ alkyl-aryl, -C₁-C₈ alkyl-(C₃-C₈ carbocycle), -C₃-C₈ heterocycle and -C₁-C₈ alkyl-(C₃-C₈ heterocycle);

each R^{14} is independently -H or -C₁-C₈ alkyl;

R^{16} is A'_a-W_w-Y_y-

wherein

each -W- is independently an Amino Acid unit;

-Y- is a Spacer unit;


w is an integer ranging from 0 to 12;

y is 0, 1 or 2; [[and]]

-A' is a Stretcher unit; and

a is 0 or 1.

selected from



wherein

~~G is selected from Cl, Br, I, O mesyl and O tosyl;~~

~~J is selected from Cl, Br, I, F, OH, O N succinimide, O (4 nitrophenyl), O pentafluorophenyl, O tetrafluorophenyl and O C(O)OR¹⁸;~~


~~a is 0 or 1;~~

~~R¹⁷ is selected from C₄-C₁₀ alkylene, C₃-C₈ carbocyclo, O (C₄-C₈ alkoxy), arylene, C₄-C₁₀ alkylene arylene, arylene C₄-C₁₀ alkylene, C₄-C₁₀ alkylene (C₃-C₈ carbocyclo), (C₃-C₈ carbocyclo) C₄-C₁₀ alkylene, C₃-C₈ heterocyclo, C₄-C₁₀ alkylene (C₃-C₈ heterocyclo), (C₃-C₈ heterocyclo) C₄-C₁₀ alkylene, (CH₂CH₂O)_f, and (CH₂CH₂O)_f-CH₂;~~

~~r is an integer ranging from 1-10; and~~


~~R¹⁸ is C₁-C₈ alkyl or aryl.~~

45. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.


46. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.


47. (Canceled)


48. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

49. (Previously Presented) The compound of claim 44 having the structure






or a pharmaceutically acceptable salt or solvate thereof.

50-51. (Canceled)


52. (Original) The compound of claim 44 having the structure



or a pharmaceutically acceptable salt or solvate thereof.

53. (Canceled)


54. (Original) The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

55. (Canceled)


56. (Original) The compound of claim 1 having the structure



where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

57-58. (Canceled)

59. (Original) The compound of claim 1 having the structure





where p ranges from 1 to about 20, or a pharmaceutically acceptable salt or solvate thereof.

60-62. (Canceled)

63. (Previously Presented)

The compound of claim 1 having the structure






64-65. (Canceled)

67-76. (Canceled)

77. (Currently Amended) The compound of claim 1 having the formula




Page 17 of 24

where p ranges from about 1 to about 8 ~~7 to about 9, from about 3 to about 5, or about 1 to about 3~~, wherein L is ~~cBR96, cAC10, an anti-CD40 antibody or an anti-CD20 antibody~~ and L is a monoclonal antibody.

78. (Canceled)

79. (Currently Amended) The compound of claim 1 having the formula



or a pharmaceutically acceptable salt or solvate thereof,

where p ranges from about 1 to about 8 ~~7 to about 9, from about 3 to about 5, or about 1 to about 3~~, wherein L is ~~cBR96, cAC10, an anti-CD40 antibody or an anti-CD20 antibody~~ and L is a monoclonal antibody.

80-99. (Canceled)

100. (Currently Amended) The compound of claim 79 wherein L is ~~rituximab~~ specifically binds the CD20 antigen.

101. (Canceled)

102. (Canceled)

103. (Canceled)

104. (Currently Amended) The compound of claim 77 wherein L ~~[[is]]~~
~~rituximab~~ specifically binds the CD20 antigen.

105-110. (Canceled)

111. (Currently Amended) A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, ~~[[44]]~~, 77, 79, ~~[[99]]~~, 100, 102 or 104 and a pharmaceutically acceptable carrier or vehicle.

112. (Currently Amended) A method for killing or inhibiting the multiplication of a tumor cell or cancer cell comprising administering to an animal in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 54, 63, ~~[[44]]~~, 77, 79, ~~[[99]]~~, 100, 102 or 104.

113. (Currently Amended) A method for treating cancer, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 54, 63, ~~[[44]]~~, 77, 79, ~~[[99]]~~, 100, 102 or 104.

114. (Currently Amended) A method for treating an autoimmune disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, 54, 63, ~~[[44]]~~, 77, 79, ~~[[99]]~~, 100, 102 or 104.

115. (Currently Amended) A method for treating an infectious disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt or solvate of the compound of any one of claims 1, ~~[[44]]~~, 77, 79, ~~[[99]]~~, 100, 102 or 104.

116. (Original) The method of claim 113 further comprising administering to the animal an effective amount of an anticancer agent.

117. (Original) The method of claim 114 further comprising administering to the animal an effective amount of an immunosuppressant agent.










118. (Original) The method of claim 115 further comprising administering to the animal an effective amount of an anti-infectious agent.

119. (Currently Amended) The compound or a pharmaceutically acceptable salt or solvate thereof of any one of claims 1, 44, 77, 79, [[99]], 100, 102 or 104, in an isolated or a purified form.

120. (New) The compound of claim 1, wherein y is 1 or 2.

121. (New) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -W_w- is-valine-citrulline-, the amino terminus of -W_w- forming a bond with a Stretcher unit, and the C- terminus of -W_w- forming a bond with a Spacer unit.

122. (New) The compound of claim 44 or a pharmaceutically acceptable salt or solvate of the compound of claim 44, wherein
-A' is selected from



wherein

G is selected from -Cl, -Br, -I, -O-mesyl and -O-tosyl;

J is selected from -Cl, -Br, -I, -F, -OH, -O-N-succinimide, -O-(4-nitrophenyl), -O-pentafluorophenyl, -O-tetrafluorophenyl and -O-C(O)-OR¹⁸;


a is 0 or 1;

R¹⁷ is selected from -C₁-C₁₀ alkylene-, -C₃-C₈ carbocyclo-, -O-(C₁-C₈ alkoxy)-, -arylene-, -C₁-C₁₀ alkylene-arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)-, -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-, -(CH₂CH₂O)_r-, and - (CH₂CH₂O)_r-CH₂-;

r is an integer ranging from 1-10; and

R¹⁸ is -C₁-C₈ alkyl or -aryl.

123. (New) The compound or a pharmaceutically acceptable salt or solvate of the compound of claim 1 where -A- is



and r is an integer ranging from 1-10, the amidomethyl terminus of -A- forming a bond with a Ligand unit.